VistaGen Therapeutics (VTGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

VTGN Stock Forecast

VistaGen Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 138.10% upside from VTGN’s last price of $2.52) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

VTGN Price Target

The average price target for VistaGen Therapeutics (VTGN) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 138.10% upside from VTGN's last price of $2.52.

VTGN Analyst Ratings

Buy

According to 3 Wall Street analysts, VistaGen Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VTGN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

VistaGen Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 22, 2022	Andrew Tsai	Jefferies	$6.00	$4.38	37.08%	138.10%

The latest VistaGen Therapeutics stock forecast, released on Jul 22, 2022 by Andrew Tsai from Jefferies, set a price target of $6.00, which represents a 37.08% increase from the stock price at the time of the forecast ($4.38), and a 138.10% increase from VTGN last price ($2.52).

VistaGen Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.52	$2.52	$2.52
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of VistaGen Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VistaGen Therapeutics's last price of $2.52. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	New Rating	Rating Change
Aug 07, 2023	Maxim Group	Buy	Upgrade
Apr 26, 2022	Zacks Investment Research	Hold	Downgrade
Feb 18, 2021	Jefferies	Buy	Initialise

VistaGen Therapeutics's last stock rating was published by Maxim Group on Aug 07, 2023. The company Upgrade its VTGN rating from "null" to "Buy".

VistaGen Therapeutics Financial Forecast

VistaGen Therapeutics Revenue Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	$411.40K	$277.70M	$177.60M	$175.60K	$179.60K	$179.60M	$310.10K	$38.90K	$357.90K	$358.00K	$354.10K	$441.90K	$313.60K	$334.00K
Avg Forecast	$97.60K	$130.15K	$173.55K	$231.35K	$308.50K	$308.50K	$224.67K	$298.65K	$405.70K	$726.00K	$184.60K	$184.60K	$179.60K	$310.10K	$310.05K	$238.63K	$338.63K	$338.67K	$351.37K	$394.63K	$304.53K	$334.00K	$2.50M
High Forecast	$168.09K	$224.15K	$298.89K	$398.44K	$531.30K	$531.30K	$386.93K	$298.82K	$405.85K	$1.49M	$317.92K	$317.92K	$309.31K	$534.06K	$310.05K	$238.63K	$338.63K	$338.67K	$351.37K	$394.63K	$304.53K	$334.00K	$2.50M
Low Forecast	$27.11K	$36.15K	$48.21K	$64.26K	$85.69K	$85.69K	$62.41K	$298.48K	$405.55K	$278.46K	$51.28K	$51.28K	$49.89K	$86.14K	$310.05K	$238.63K	$338.63K	$338.67K	$351.37K	$394.63K	$304.53K	$334.00K	$2.50M
# Analysts	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	0.57%	1504.33%	962.08%	0.98%	0.58%	579.26%	1.30%	0.11%	1.06%	1.02%	0.90%	1.45%	0.94%	0.13%

VistaGen Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $405.70K, with a low forecast of $405.55K, and a high forecast of $405.85K. VTGN's average Quarter revenue forecast represents a -1.39% decrease compared to the company's last Quarter revenue of $411.40K (Dec 23).

VistaGen Therapeutics EBITDA Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-7.74M	$-6.78B	$-7.00B	$-12.09M	$-9.62M	$-17.34M	$-19.64M	$-16.55M	$-10.22M	$-12.57M	$-7.71M	$-6.17M	$-5.27M	$-3.27M
Avg Forecast	$-19.52K	$-26.03K	$-34.71K	$-46.27K	$-61.70K	$-61.70K	$-44.93K	$-59.73K	$-81.14K	$-145.20K	$-36.92K	$-36.92K	$-35.92K	$-62.02K	$-62.01K	$-47.73K	$-67.73K	$-67.73K	$-70.27K	$-9.25M	$-60.91K	$-66.80K	$-500.00K
High Forecast	$-5.42K	$-7.23K	$-9.64K	$-12.85K	$-17.14K	$-17.14K	$-12.48K	$-59.69K	$-81.11K	$-55.69K	$-10.26K	$-10.26K	$-9.98K	$-17.23K	$-62.01K	$-47.73K	$-67.73K	$-67.73K	$-70.27K	$-7.40M	$-60.91K	$-66.80K	$-500.00K
Low Forecast	$-33.62K	$-44.83K	$-59.78K	$-79.69K	$-106.26K	$-106.26K	$-77.39K	$-59.76K	$-81.17K	$-298.36K	$-63.58K	$-63.58K	$-61.86K	$-106.81K	$-62.01K	$-47.73K	$-67.73K	$-67.73K	$-70.27K	$-11.10M	$-60.91K	$-66.80K	$-500.00K
Surprise %	-	-	-	-	-	-	-	-	-	53.31%	183650.69%	189544.68%	336.49%	155.16%	279.66%	411.46%	244.44%	150.87%	178.83%	0.83%	101.30%	78.88%	6.53%

undefined analysts predict VTGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VistaGen Therapeutics's previous annual EBITDA (undefined) of $NaN.

VistaGen Therapeutics Net Income Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-6.35M	$-6.59B	$-6.90B	$-12.23M	$-9.83M	$-17.48M	$-19.78M	$-16.68M	$-10.54M	$-12.79M	$-7.74M	$-6.21M	$-5.30M	$-3.30M
Avg Forecast	$-17.46M	$-16.69M	$-17.92M	$-16.39M	$-16.92M	$-15.62M	$-11.97M	$-12.34M	$-11.10M	$-9.27M	$-20.83M	$-26.34M	$-45.95M	$-62.77M	$-61.21M	$-73.45M	$-52.79M	$-66.56M	$-52.79M	$-9.29M	$-43.61M	$-48.97M	$-21.42M
High Forecast	$-1.07M	$-1.02M	$-1.10M	$-1.00M	$-15.78M	$-14.69M	$-731.61K	$-754.22K	$-678.59K	$-8.07M	$-1.27M	$-1.61M	$-2.81M	$-3.84M	$-61.21M	$-73.45M	$-52.79M	$-66.56M	$-52.79M	$-7.43M	$-43.61M	$-48.97M	$-21.42M
Low Forecast	$-33.85M	$-32.37M	$-34.74M	$-31.78M	$-17.50M	$-16.56M	$-23.21M	$-23.93M	$-21.53M	$-11.66M	$-40.39M	$-51.08M	$-89.09M	$-121.70M	$-61.21M	$-73.45M	$-52.79M	$-66.56M	$-52.79M	$-11.15M	$-43.61M	$-48.97M	$-21.42M
Surprise %	-	-	-	-	-	-	-	-	-	0.69%	316.26%	261.94%	0.27%	0.16%	0.29%	0.27%	0.32%	0.16%	0.24%	0.83%	0.14%	0.11%	0.15%

VistaGen Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VTGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

VistaGen Therapeutics SG&A Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$3.76M	$3.21B	$2.98B	$3.15M	$3.02M	$3.70M	$4.79M	$4.96M	$2.93M	$3.09M	$2.26M	$1.77M	$2.12M	$1.27M
Avg Forecast	$-589.59K	$-786.21K	$-1.05M	$-1.40M	$-1.86M	$-1.86M	$-1.36M	$-1.80M	$-2.45M	$-4.39M	$-1.12M	$-1.12M	$-1.08M	$-1.87M	$-1.87M	$-1.44M	$-2.05M	$-2.05M	$-2.12M	$-2.38M	$-1.84M	$-2.02M	$-15.10M
High Forecast	$-163.77K	$-218.39K	$-291.22K	$-388.20K	$-517.66K	$-517.66K	$-376.99K	$-1.80M	$-2.45M	$-1.68M	$-309.76K	$-309.76K	$-301.37K	$-520.35K	$-1.87M	$-1.44M	$-2.05M	$-2.05M	$-2.12M	$-2.38M	$-1.84M	$-2.02M	$-15.10M
Low Forecast	$-1.02M	$-1.35M	$-1.81M	$-2.41M	$-3.21M	$-3.21M	$-2.34M	$-1.81M	$-2.45M	$-9.01M	$-1.92M	$-1.92M	$-1.87M	$-3.23M	$-1.87M	$-1.44M	$-2.05M	$-2.05M	$-2.12M	$-2.38M	$-1.84M	$-2.02M	$-15.10M
Surprise %	-	-	-	-	-	-	-	-	-	-0.86%	-2876.14%	-2670.70%	-2.91%	-1.61%	-1.98%	-3.32%	-2.43%	-1.43%	-1.46%	-0.95%	-0.96%	-1.05%	-0.08%

VistaGen Therapeutics's average Quarter SG&A projection for Mar 24 is $-2.45M, based on 1 Wall Street analysts, with a range of $-2.45M to $-2.45M. The forecast indicates a -165.21% fall compared to VTGN last annual SG&A of $3.76M (Dec 23).

VistaGen Therapeutics EPS Forecast

	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-0.22	$-0.66	$-0.94	-	$-0.05	$-0.08	$-0.10	$-0.08	$-0.05	$-0.07	$-0.04	$-0.07	$-0.07	$-0.05
Avg Forecast	$-0.57	$-0.55	$-0.58	$-0.54	$-0.55	$-0.51	$-0.39	$-0.40	$-0.36	$-0.30	$-0.68	$-0.86	$-1.50	$-2.05	$-2.00	$-2.40	$-1.73	$-2.17	$-1.73	$-1.60	$-1.43	$-1.60	$-0.70
High Forecast	$-0.03	$-0.03	$-0.04	$-0.03	$-0.52	$-0.48	$-0.02	$-0.02	$-0.02	$-0.26	$-0.04	$-0.05	$-0.09	$-0.13	$-2.00	$-2.40	$-1.73	$-2.17	$-1.73	$-1.60	$-1.43	$-1.60	$-0.70
Low Forecast	$-1.11	$-1.06	$-1.13	$-1.04	$-0.57	$-0.54	$-0.76	$-0.78	$-0.70	$-0.38	$-1.32	$-1.67	$-2.91	$-3.97	$-2.00	$-2.40	$-1.73	$-2.17	$-1.73	$-1.60	$-1.43	$-1.60	$-0.70
Surprise %	-	-	-	-	-	-	-	-	-	0.73%	0.97%	1.09%	-	0.02%	0.04%	0.04%	0.05%	0.02%	0.04%	0.02%	0.05%	0.04%	0.07%

According to undefined Wall Street analysts, VistaGen Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VTGN previous annual EPS of $NaN (undefined).

VistaGen Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRMA	Dermata Therapeutics	$1.10	$6.00	445.45%	Buy
ACIU	AC Immune SA	$2.94	$9.00	206.12%	Buy
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
VTGN	VistaGen Therapeutics	$2.43	$6.00	146.91%	Buy
XBIO	Xenetic Biosciences	$4.07	$4.00	-1.72%

VTGN Forecast FAQ

Is VistaGen Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, VistaGen Therapeutics (VTGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of VTGN's total ratings.

What is VTGN's price target?

VistaGen Therapeutics (VTGN) average price target is $6 with a range of $6 to $6, implying a 138.10% from its last price of $2.52. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will VistaGen Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VTGN stock, the company can go up by 138.10% (from the last price of $2.52 to the average price target of $6), up by 138.10% based on the highest stock price target, and up by 138.10% based on the lowest stock price target.

Can VistaGen Therapeutics stock reach $4?

VTGN's average twelve months analyst stock price target of $6 supports the claim that VistaGen Therapeutics can reach $4 in the near future.

What are VistaGen Therapeutics's analysts' financial forecasts?

VistaGen Therapeutics's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $1.14M (high $1.75M, low $532.27K), average EBITDA is $-228K (high $-106K, low $-350K), average net income is $-56.86M (high $-31.948M, low $-81.199M), average SG&A $-6.888M (high $-3.215M, low $-10.562M), and average EPS is $-1.856 (high $-1.043, low $-2.651). VTGN's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $632.65K (high $1.09M, low $175.73K), average EBITDA is $-127K (high $-35.145K, low $-218K), average net income is $-68.463M (high $-4.184M, low $-133M), average SG&A $-3.822M (high $-1.062M, low $-6.582M), and average EPS is $-2.235 (high $-0.137, low $-4.333).

Did the VTGN's actual financial results beat the analysts' financial forecasts?

Based on VistaGen Therapeutics's last annual report (Mar 2023), the company's revenue was $-227M, which missed the average analysts forecast of $1.04M by -21989.80%. Apple's EBITDA was $-59.268B, beating the average prediction of $-208K by 28538997.52%. The company's net income was $-59.248B, beating the average estimation of $-243M by 24244.77%. Apple's SG&A was $14.66B, missing the average forecast of $-6.273M by -233868.29%. Lastly, the company's EPS was $-8.51, beating the average prediction of $-7.949 by 7.06%. In terms of the last quarterly report (Dec 2023), VistaGen Therapeutics's revenue was $411.4K, missing the average analysts' forecast of $726K by -43.33%. The company's EBITDA was $-7.741M, beating the average prediction of $-145K by 5231.30%. VistaGen Therapeutics's net income was $-6.35M, missing the average estimation of $-9.266M by -31.47%. The company's SG&A was $3.76M, missing the average forecast of $-4.386M by -185.69%. Lastly, the company's EPS was $-0.22, missing the average prediction of $-0.302 by -27.27%